EQT Life Sciences has supported Amolyt since its first investment in 2019, during which the company went from preclinical stages to running a Phas[...]
New specialist European and US life sciences investors join existing investors to enable Nouscom to continue advancing the clinical development of [...]
EQT Life Sciences has invested in Asceneuron’s oversubscribed Series C and Prof. Philip Scheltens will join the Asceneuron Board of Directors
Asceneuron – which is developing small molecules tar [...]
Acquisition values Cardior Pharmaceuticals (“Cardior”) at up to EUR 1.025 billion, including an upfront payment and additional payments if certain development and commercial milestones are achieved
[...]
EQT Life Sciences has supported Amolyt since its first investment in 2019, during which the company went from preclinical stages to running a Phase III
The transaction is expected to close in the third q [...]
Financing round co-led by EQT Life Sciences and Nextech Invest1, with participation from other leading global biotechnology investors
Proceeds will be used to advance clinical trials of lead solid tumor targete [...]
Onera Health, a leader in sleep diagnostic and monitoring solutions, closed a €30M ($32M) Series C financing round. The all-equity round was led by EQT Life Sciences and co-led by Gimv, with existing investors Innov [...]
Phagenesis, a medical devices company, which specializes in the treatment of swallowing disorders, successfully closes a $42M Series D financing round led by EQT Life Sciences and co-led by Sectoral Asset Management [...]
EQT Life Sciences has invested in Asceneuron’s oversubscribed Series C and Prof. Philip Scheltens will join the Asceneuron Board of Directors
Asceneuron – which is developing small molecules tar[...]
Acquisition values Cardior Pharmaceuticals (“Cardior”) at up to EUR 1.025 billion, including an upfront payment and additional payments if certain development and commercial milestones are achieved
[...]
EQT Life Sciences has supported Amolyt since its first investment in 2019, during which the company went from preclinical stages to running a Phase III
The transaction is expected to close in the third q[...]
Financing round co-led by EQT Life Sciences and Nextech Invest1, with participation from other leading global biotechnology investors
Proceeds will be used to advance clinical trials of lead solid tumor targete[...]
Phagenesis, a medical devices company, which specializes in the treatment of swallowing disorders, successfully closes a $42M Series D financing round led by EQT Life Sciences and co-led by Sectoral Asset Management[...]
Onera Health, a leader in sleep diagnostic and monitoring solutions, closed a €30M ($32M) Series C financing round. The all-equity round was led by EQT Life Sciences and co-led by Gimv, with existing investors Innov[...]
Round co-led by EQT Life Sciences and Forbion
Series A financing will support clinical development of the lead program in amyotrophic lateral sclerosis (ALS) and preclinical development of pip[...]
New specialist European and US life sciences investors join existing investors to enable Nouscom to continue advancing the clinical development of its portfolio of neoantigen cancer vaccines to key clinical proof of c[...]
Amsterdam, The Netherlands, October 16, 2023 - EQT Life Sciences is happy to announce an investment from the LSP Dementia Fund into AstronauTx Ltd. (“AstronauTx” or “the Company”), a UK based biotech compan[...]
EQT Life Sciences leads investment in MinervaX with OrbiMed also joining as a new investor
The financing will advance the development of MinervaX’s maternal vaccine against Group B Streptococcus and he[...]
EQT Life Sciences has invested in Asceneuron’s oversubscribed Series C and Prof. Philip Scheltens will join the Asceneuron Board of Directors
Asceneuron – which is developing small molecules tar [...]
Acquisition values Cardior Pharmaceuticals (“Cardior”) at up to EUR 1.025 billion, including an upfront payment and additional payments if certain development and commercial milestones are achieved
[...]
EQT Life Sciences has supported Amolyt since its first investment in 2019, during which the company went from preclinical stages to running a Phase III
The transaction is expected to close in the third q [...]
Financing round co-led by EQT Life Sciences and Nextech Invest1, with participation from other leading global biotechnology investors
Proceeds will be used to advance clinical trials of lead solid tumor targete [...]
Onera Health, a leader in sleep diagnostic and monitoring solutions, closed a €30M ($32M) Series C financing round. The all-equity round was led by EQT Life Sciences and co-led by Gimv, with existing investors Innov [...]
Phagenesis, a medical devices company, which specializes in the treatment of swallowing disorders, successfully closes a $42M Series D financing round led by EQT Life Sciences and co-led by Sectoral Asset Management [...]
Follow us
